Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.83 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.83 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | CA3 | P07451 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257898 | 0.98 | ESR1 (0.83) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL1256665 | 0.98 | ESR1 (0.83) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL1257273 | 0.98 | ESR1 (0.83) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL23506629 | 0.98 | ESR1 (0.83) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 | |
| Phenol SCHEMBL8634617 | 0.94 | ESR1 (0.83) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 | |
| Phenol SCHEMBL29040626 | 0.94 | ESR1 (0.83) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 | |
| Phenol SCHEMBL29118790 | 0.91 | ESR1 (0.72) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 | |
| SCHEMBL30738223 | 0.91 | ESR1 (0.67) | ESR1ESR2OPRM1MEN1KMT2A | |
| SCHEMBL120895 | 0.91 | ESR2 (1.00) | ESR1ESR2ALDH1A1L3MBTL1MEN1 | |
| SCHEMBL13379655 | 0.89 | ESR2 (1.00) | ESR1ESR2OPRM1ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-11072679-B2 | Polyurethanes prepared from oligomeric polyol compositions and polyisocyanates | PRESIDIUM USA, INC (US) | 2021-07-27 | — | — | US | disclosed |
| US-11066512-B2 | Method of preparing oligomeric polyol compositions | PRESIDIUM USA, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190055346-A1 | Method of Preparing Oligomeric Polyol Compositions | PRESIDIUM INNOVATIONS, LLC | 2019-02-21 | — | — | US | disclosed |
| US-20190055345-A1 | Polyurethanes Prepared from Oligomeric Polyol Compositions and Polyisocyanates | PRESIDIUM INNOVATIONS, LLC | 2019-02-21 | — | — | US | disclosed |
| EP-2373163-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH INC (US) | 2015-06-10 | — | — | EP | disclosed |
| US-8232273-B2 | Heterocyclic compounds and methods of use | GENENTECH, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2373163-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Genentech, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2010-08-19 | — | — | US | disclosed |
| WO-2010080503-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210622-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BCL2A1, BAX, BCL2 | ESR1 415/4885ESR2 260/4885OPRM1 1451/4885 |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | ESR1 778/4885ESR2 296/4885OPRM1 3875/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | ESR1 778/4885ESR2 296/4885OPRM1 3875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.